Details of the Drug Combination

General Information of Drug Combination (ID: DCHO64D)

Drug Combination Name

Droxidopa Pyridostigmine

Indication

Disease Entry	Status	REF
Orthostatic Hypotension	Phase 1	[1]

Component Drugs

Droxidopa DM5YF4M

Pyridostigmine DM8HO1L

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Droxidopa

Disease Entry	ICD 11	Status	REF
Chronic fatigue syndrome	8E49	Approved	[2]
Neurogenic orthostatic hypotension	8D87.0Y	Approved	[3]
Pure autonomic failure	N.A.	Approved	[2]

Droxidopa Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
DOPA decarboxylase (DDC)	DETK9CN	DDC_HUMAN	Metabolism	[6]
------------------------------------------------------------------------------------

Indication(s) of Pyridostigmine

Pyridostigmine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[7]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01370512) Droxidopa / Pyridostigmine in Orthostatic Hypotension
2	Droxidopa FDA Label
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7391).
4	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040457.
5	ClinicalTrials.gov (NCT04343963) Pyridostigmine in Severe SARS-CoV-2 Infection. U.S. National Institutes of Health.
6	L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):189-203.
7	Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50.